Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease

Journal of the American College of Cardiology

Volumn 47, Issue 3, 2006, Pages 492-499

  Barter, Philip J ^a   Kastelein, John J P ^b  

^a HEART RESEARCH INSTITUTE   (Australia)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; TORCETRAPIB;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG INHIBITION; HUMAN; LIPID TRANSPORT; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; GLYCOPROTEINS; HUMANS; QUINOLINES; RISK FACTORS; SULFHYDRYL COMPOUNDS; VACCINES;

EID: 31644445200     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.09.042     Document Type: Review

References (65)

1. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, T.R. Dawber High density lipoprotein as a protective factor against coronary heart disease. The Framingham study Am J Med 62 1977 707 714
2. G. Assmann, H. Schulte, A. von Eckardstein, Y. Huang High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport Atherosclerosis 124 Suppl 1996 S11 S20
3. D.J. Gordon, J.L. Probstfield, R.J. Garrison High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15
4. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
5. S.J. Robins, D. Collins, J.T. Wittes Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591
6. V. Manninen, L. Tenkanen, P. Koskinen Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart study. Implications for treatment Circulation 85 1992 37 45
7. P.L. Canner, K.G. Berge, N.K. Wenger Fifteen year mortality in Coronary Drug Project patients long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
8. Scandinavian Simvastatin Survival Study Group Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S) Lancet 345 1995 1274 1275
9. A.M. Gotto Jr., E.A. Brinton Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease a working group report and update J Am Coll Cardiol 43 2004 717 724
10. P.J. Barter, H.B. Brewer Jr., M.J. Chapman, C.H. Hennekens, D.J. Rader, A.R. Tall Cholesteryl ester transfer protein a novel target for raising HDL and inhibiting atherosclerosis Arterioscler Thromb Vasc Biol 23 2003 160 167
11. J.N. Chapman Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C Curr Med Res Opin 20 2004 1253 1268
12. G. Assmann, A.M. Gotto Jr. HDL cholesterol and protective factors in atherosclerosis Circulation 109 2004 III8 III14
13. L. Calabresi, M. Gomaraschi, G. Franceschini Endothelial protection by high-density lipoproteins from bench to bedside Arterioscler Thromb Vasc Biol 23 2003 1724 1731
14. D.J. Rader, K.A. Dugi The endothelium and lipoproteins insights from recent cell biology and animal studies Semin Thromb Hemost 26 2000 521 528
15. C.C. Schwartz, J.M. VandenBroek, P.S. Cooper Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans J Lipid Res 45 2004 1594 1607
16. D.L. Williams, M.A. Connelly, R.E. Temel Scavenger receptor BI and cholesterol trafficking Curr Opin Lipidol 10 1999 329 339
17. P.G. Yancey, A.E. Bortnick, G. Kellner-Weibel, M. de la Llera-Moya, M.C. Phillips, G.H. Rothblat Importance of different pathways of cellular cholesterol efflux Arterioscler Thromb Vasc Biol 23 2003 712 719
18. N. Wang, D. Lan, W. Chen, F. Matsuura, A.R. Tall ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins Proc Natl Acad Sci U S A 101 2004 9774 9779
19. K. Nakamura, M.A. Kennedy, A. Baldan, D.D. Bojanic, K. Lyons, P.A. Edwards Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein J Biol Chem 279 2004 45980 45989
20. A.R. Tall Plasma cholesteryl ester transfer protein J Lipid Res 34 1993 1255 1274
21. G.J. de Grooth, A.H. Klerkx, E.S. Stroes, A.F. Stalenhoef, J.J. Kastelein, J.A. Kuivenhoven A review of CETP and its relation to atherosclerosis J Lipid Res 45 2004 1967 1974
22. G.J. de Grooth, T.J. Smilde, S. Van Wissen The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia Atherosclerosis 173 2004 261 267
23. R. McPherson, C.J. Mann, A.R. Tall Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables Arterioscler Thromb 11 1991 797 804
24. P. Moulin, G.B. Appel, H.N. Ginsberg, A.R. Tall Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome role in dyslipidemia J Lipid Res 33 1992 1817 1822
25. A. Van Tol CETP-catalysed transfer of cholesterylesters from HDL to apo B-containing lipoproteins in plasma from diabetic patients Eur J Clin Invest 23 1993 856
26. B.H. Chung, J.P. Segrest, F. Franklin In vitro production of beta-very low density lipoproteins and small, dense low density lipoproteins in mildly hypertriglyceridemic plasma role of activities of lecithin:cholester acyltransferase, cholesterylester transfer proteins and lipoprotein lipase Atherosclerosis 141 1998 209 225
27. R.M. Krauss Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk Curr Opin Lipidol 5 1994 339 349
28. V. Anber, B.A. Griffin, M. McConnell, C.J. Packard, J. Shepherd Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans Atherosclerosis 124 1996 261 271
29. A. Chait, R.L. Brazg, D.L. Tribble, R.M. Krauss Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B Am J Med 94 1993 350 356
30. D.L. Tribble, J.J. van den Berg, P.A. Motchnik Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and alpha-tocopherol content Proc Natl Acad Sci U S A 91 1994 1183 1187
31. K.A. Rye, M.A. Clay, P.J. Barter Remodelling of high density lipoproteins by plasma factors Atherosclerosis 145 1999 227 238
32. W. Le Goff, M. Guerin, M.J. Chapman Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia Pharmacol Ther 101 2004 17 38
33. B.S. Horowitz, I.J. Goldberg, J. Merab, T.M. Vanni, R. Ramakrishnan, H.N. Ginsberg Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol J Clin Invest 91 1993 1743 1752
34. A. Inazu, M.L. Brown, C.B. Hesler Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation N Engl J Med 323 1990 1234 1238
35. M.L. Brown, A. Inazu, C.B. Hesler Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins Nature 342 1989 448 451
36. T. Hayek, N. Azrolan, R.B. Verdery Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice J Clin Invest 92 1993 1143 1152
37. M. Guerin, W. Le Goff, T.S. Lassel, A. Van Tol, G. Steiner, M.J. Chapman Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes impact of the degree of triglyceridemia Arterioscler Thromb Vasc Biol 21 2001 282 288
38. J.C. Hogue, B. Lamarche, D. Gaudet Relationship between cholesteryl ester transfer protein and LDL heterogeneity in familial hypercholesterolemia J Lipid Res 45 2004 1077 1083
39. K.R. Marotti, C.K. Castle, T.P. Boyle, A.H. Lin, R.W. Murray, G.W. Melchior Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein Nature 364 1993 73 75
40. A.S. Plump, L. Masucci-Magoulas, C. Bruce, C.L. Bisgaier, J.L. Breslow, A.R. Tall Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression Arterioscler Thromb Vasc Biol 19 1999 1105 1110
41. van der Hoogt CC, Westerterp M, de Haan W, et al. CETP expression decreases HDL and severely aggravates atherosclerosis in APOE* (*)3-Leiden mice. Presentation at the Dutch Atherosclerosis Society, March 17 to 18, 2005
42. T. Hayek, L. Masucci-Magoulas, X. Jiang Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene J Clin Invest 96 1995 2071 2074
43. Y. Kako, M. Masse, L.S. Huang, A.R. Tall, I.J. Goldberg Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice J Lipid Res 43 2002 872 877
44. M. Sugano, N. Makino, S. Sawada Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits J Biol Chem 273 1998 5033 5036
45. C.W. Rittershaus, D.P. Miller, L.J. Thomas Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis Arterioscler Thromb Vasc Biol 20 2000 2106 2112
46. H. Okamoto, F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, H. Shinkai A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits Nature 406 2000 203 207
47. Z. Huang, A. Inazu, A. Nohara, T. Higashikata, H. Mabuchi Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia Clin Sci (Lond) 103 2002 587 594
48. Morehouse LA, Sugarman ED, Bourassa PA, Milici AJ. The CETP-inhibitor torcetrapib raises HDL and prevents aortic atherosclerosis in rabbits. Presented at: XV International Symposium on Drugs Affecting Lipid Metabolism, October 24 to 27, 2004, Venice, Italy.
49. T. Maruyama, N. Sakai, M. Ishigami Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia Atherosclerosis 166 2003 177 185
50. K. Hirano, S. Yamashita, Y. Kuga Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase Arterioscler Thromb Vasc Biol 15 1995 1849 1856
51. S. Zhong, D.S. Sharp, J.S. Grove Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels J Clin Invest 97 1996 2917 2923
52. J.D. Curb, R.D. Abbott, B.L. Rodriguez A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly J Lipid Res 45 2004 948 953
53. S.M. Boekholdt, J.F. Thompson Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease J Lipid Res 44 2003 1080 1093
54. D. Corella, C. Saiz, M. Guillen Association of TaqIB polymorphism in the cholesteryl ester transfer protein gene with plasma lipid levels in a healthy Spanish population Atherosclerosis 152 2000 367 376
55. J.M. Ordovas, L.A. Cupples, D. Corella Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk the Framingham study Arterioscler Thromb Vasc Biol 20 2000 1323 1329
56. S.M. Boekholdt, F.M. Sacks, J.W. Jukema Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment individual patient meta-analysis of 13,677 subjects Circulation 111 2005 278 287
57. N. Barzilai, G. Atzmon, C. Schechter Unique lipoprotein phenotype and genotype associated with exceptional longevity JAMA 290 2003 2030 2040
58. A.H. Klerkx, G.J. de Grooth, A.H. Zwinderman, J.W. Jukema, J.A. Kuivenhoven, J.J. Kastelein Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS) Eur J Clin Invest 34 2004 21 28
59. S.M. Boekholdt, J.A. Kuivenhoven, N.J. Wareham Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk Population study Circulation 110 2004 1418 1423
60. M.H. Davidson, K. Maki, D. Umporowicz, A. Wheeler, C. Rittershaus, U. Ryan The safety and immunogenicity of a CETP vaccine in healthy adults Atherosclerosis 169 2003 113 120
61. G.J. de Grooth, J.A. Kuivenhoven, A.F. Stalenhoef Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans a randomized phase II dose-response study Circulation 105 2002 2159 2165
62. J.A. Kuivenhoven, G.J. de Grooth, H. Kawamura, A.H. Klerkx, F. Wilhelm, J.J.P. Kastelein Inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia Am J Cardiol 95 2005 1085 1088
63. R.W. Clark, T.A. Sutfin, R.B. Ruggeri Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein an initial multidose study of torcetrapib Arterioscler Thromb Vasc Biol 24 2004 490 497
64. M.E. Brousseau, E.J. Schaefer, M.L. Wolfe Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N Engl J Med 350 2004 1505 1515
65. M.E. Brousseau, M.R. Diffenderfer, J.S. Millar Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion Arterioscler Thromb Vasc Biol 25 2005 1057 1064